Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Inspire Veterinary Partners (IVPR) Capital Expenditures (2022 - 2025)

Historic Capital Expenditures for Inspire Veterinary Partners (IVPR) over the last 4 years, with Q3 2025 value amounting to $43461.0.

  • Inspire Veterinary Partners' Capital Expenditures rose 7030.84% to $43461.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $108143.0, marking a year-over-year decrease of 5294.1%. This contributed to the annual value of $237983.0 for FY2024, which is 3798.17% down from last year.
  • Inspire Veterinary Partners' Capital Expenditures amounted to $43461.0 in Q3 2025, which was up 7030.84% from $12579.0 recorded in Q2 2025.
  • Inspire Veterinary Partners' Capital Expenditures' 5-year high stood at $240550.0 during Q3 2023, with a 5-year trough of -$3.3 million in Q4 2022.
  • Over the past 4 years, Inspire Veterinary Partners' median Capital Expenditures value was $24605.0 (recorded in 2024), while the average stood at -$218271.2.
  • Examining YoY changes over the last 5 years, Inspire Veterinary Partners' Capital Expenditures showed a top increase of 102087.56% in 2024 and a maximum decrease of 8939.14% in 2024.
  • Quarter analysis of 4 years shows Inspire Veterinary Partners' Capital Expenditures stood at -$3.3 million in 2022, then skyrocketed by 100.71% to $23648.0 in 2023, then soared by 34.59% to $31828.0 in 2024, then skyrocketed by 36.55% to $43461.0 in 2025.
  • Its Capital Expenditures stands at $43461.0 for Q3 2025, versus $12579.0 for Q2 2025 and $20275.0 for Q1 2025.